ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

November 12, 2021 GMT

MASON, Ohio--(BUSINESS WIRE)--Nov 12, 2021--

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Piper Sandler 33 rd Annual Virtual Healthcare Conference.

ADVERTISEMENT

AtriCure’s prerecorded fireside chat will be available on Monday, November 22, 2021 on the conference and company’s website. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com. Management will participate in investor meetings on Wednesday, December 1, 2021.

About AtriCure

ADVERTISEMENT

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator ® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE ® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211112005242/en/

CONTACT: Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.comLynn Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

lynn@gilmartinir.com

KEYWORD: UNITED STATES NORTH AMERICA OHIO

INDUSTRY KEYWORD: RESEARCH CONSUMER MEDICAL DEVICES HOSPITALS SURGERY CLINICAL TRIALS SCIENCE OTHER CONSUMER CARDIOLOGY BIOTECHNOLOGY ALTERNATIVE MEDICINE FDA HEALTH

SOURCE: AtriCure, Inc.

Copyright Business Wire 2021.

PUB: 11/12/2021 08:00 AM/DISC: 11/12/2021 08:01 AM

http://www.businesswire.com/news/home/20211112005242/en